A. Falcone

Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC)

IntroductionREG is a multi-kinase inhibitor that improves overall survival vs placebo in refractory mCRC. However, REG adverse tolerability profile often limits its use on normal clinica...

T. Cano ;

F. Loupakis ;

Josep Tabernero , MD, PhD;

M. Rodriguez Garrote ;

F. Herrero Rivera ;

R. Goldberg ;

J. Bennouna ;

Fortunato Ciardiello ;

A. Falcone ;

E. Aranda ;

G. Argiles ;

N. Mulet Margalef ;

M. Valladares-Ayerbes ;

J. Vieitez de Prado ;

C. Gravalos ;

P. Garcia Alfonso ;

C. Santos ;

M. Tobena ;

J. Sastre ;

M. Benavides ;

07/01/2019

Prospective validation of Ang-2 and Tie-2 plasma levels as predictors of benefit from regorafenib in metastatic colorectal cancer patients: REGOLAND study

Background Regorafenib is a treatment option for refractory metastatic colorectal cancer (mCRC) patients. The identification of markers to predict or monitor the efficacy of regorafenib r...

F. Marmorino ;

Filippo Pietrantonio ;

A. Boccaccino ;

C. Cremolini ;

M. Antista ;

N. Zaffaroni ;

G. Zucchelli ;

A. Martinetti ;

E. Campi ;

E. Sottotetti ;

B. Borelli ;

F. Corti ;

V. Conca ;

R. Moretto ;

M. Germani ;

A. Falcone ;

M. Giordano ;

C. Antoniotti ;

G. Masi ;

07/02/2021

Tumor mutational load, microsatellite instability, BRCAness, and actionable alterations in metastatic colorectal cancer: Results from the TRIBE2 study

Background In the TRIBE2 study, molecularly unselected and untreated mCRC patients were randomized to receive FOLFOXIRI/bevacizumab (bev) followed by the same agents after disease progres...

T. Latiano ;

E. Tamburini ;

A. Passardi ;

Sara Lonardi ;

D. Santini ;

H. Lenz ;

A. Zaniboni ;

C. Antoniotti ;

G. Aprile ;

F. Marmorino ;

R. Bordonaro ;

G. Zucchelli ;